Bio-Cancer Treatment International

Bio-Cancer Treatment International Ltd. was established in 2000 as a clinical-stage biopharmaceutical company dedicated to the research and development of innovative biologics for the treatment of human malignant tumors and autoimmune diseases. The company's portfolio of candidate products includes BCT-100 and BCT-200, pegylated recombinant human arginase 1 (pegArg1), which are arginine depleting agents that can delay tumor growth and ultimately lead to cancer cell death. BCT-100 is currently in Phase I clinical trials in the United States for the treatment of arginine auxotrophic solid tumors and in Phase II clinical trials in Hong Kong for the treatment of acute myeloid leukemia (AML). BCT-200, featuring modifications to the amino acid sequence of BCT-100, is in the pre-IND stage.